Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07457671) titled 'TAR-0520 Gel in Hand and Foot Syndrome' on Feb. 24.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).

Primary Sponsor: Tarian Pharma

Condition: Hand and Foot Syndrome

Intervention: Drug: TAR-0520 gel

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: March 2026

Target Sample Size: 25

Countries of Recruitment: France

To know more, visit https://clinicaltrials.gov/study/NCT07457671

Disclaimer: Curated by HT Syndication....